Among the greatest scientists of the 20th century was Linus Pauling.
He won two Nobel Prizes and revolutionized our knowledge of protein structure and chemical interactions.
But at the end of his career, he gained notoriety for something quite different: his fervent conviction that cancer patients could benefit from extremely high dosages of vitamin C.
Many medical professionals sneered. Pauling was seen as a prime example of the "halo effect," which states that mastery in one area does not equate to knowledge in another, when he passed away from cancer at the age of 93.
After fifty years, the narrative appears to be more intricate.
Pauling was not totally incorrect, but he was incorrect in significant respects. It turns out that under some circumstances, vitamin C can act more like a medication than a gentle vitamin when it comes to cancer, according to current studies.
Pauling's vitamin C narrative started in the 1970s when he collaborated with Scottish physician Ewan Cameron to provide extremely high doses of vitamin C, initially as a drip into a vein and later as tablets, to patients with advanced, incurable cancer.
They reported that the vitamin-treated group felt better and lived longer than similar individuals who did not receive vitamin C. They proposed that survival might be many times longer for individuals.
This was then tested in two sizable trials conducted by the Mayo Clinic, a prestigious nonprofit medical facility in the United States. The outcome was obvious: There was no advantage.
Individuals who took vitamin C supplements did not outlive those who did not. That was the end of it for the majority of oncologists.
Pauling's late-career campaign was largely regarded as a tragic error, and vitamin C was filed away with other "alternative" medicines.
The Mayo Clinic experiments exclusively used tablets, something that neither the trial's detractors nor supporters realized at the time: Pauling and Cameron had begun with vitamin C intravenously.
This is important because the amount of vitamin C that the intestine can absorb is limited. The body simply stops absorbing much more once you reach a moderate daily dosage. Your blood's vitamin C levels will drop if you take as many tablets as you like.
In contrast, blood levels can be raised tens or even hundreds of times higher with a drip into a vein than with pills. Vitamin C begins to act differently inside the body at those severe amounts.
Vitamin C functions as an antioxidant on a daily basis, scavenging dangerous chemicals and shielding our cells. It can switch roles at very high concentrations, particularly in the vicinity of tumors.
High doses of vitamin C aid in the production of hydrogen peroxide, a reactive chemical that can harm cells, in lab experiments.
Because cancer cells are already under stress, they appear to be particularly sensitive. They create a lot of their own reactive chemicals and develop quickly, frequently in places with inadequate blood flow. They have overworked internal "cleanup" mechanisms.
Many cancer cells tip over the edge when exposed to a quick pulse of hydrogen peroxide; their DNA and energy machinery are harmed, and they perish.
Normal cells have a higher chance of surviving since they are less stressed and have stronger defenses. In this approach, very high doses of vitamin C behave less like a regular supplement and more like a weak, selective chemotherapeutic agent.
Importantly, pills cannot reach the levels required for this action.
What the most recent data indicates
The evidence in humans is still preliminary and conflicting. Patients with difficult to treat malignancies, such as ovarian pancreatic or brain tumors have received high dose vitamin C intravenously in small trials.
Large doses can currently be administered to many patients multiple times a week without causing significant negative effects. This is not a harmless wellness drip to be sold on the high street since problems can arise, particularly in persons with unusual genetic diseases or poor kidney function.
While some research indicates that adding vitamin C infusions to chemotherapy may help some people survive a bit longer or manage adverse effects, other studies find no discernible advantage.
We are unable to make definitive conclusions because the studies are tiny and diverse.
Quality of life is a reliable indicator; patients receiving vitamin C in addition to chemotherapy frequently report feeling less tired, experiencing less pain, and experiencing fewer side effects including nausea. Even if it is not the all-encompassing cure Pauling had promised, it counts to someone with terminal cancer.
Subtler responsibilities are also hinted at in lab work. Enzymes that affect how our DNA is "marked" and read, as well as how cells divide and react to low oxygen—a crucial aspect of cancer behavior—are all impacted by vitamin C.
High vitamin C levels have been shown in certain studies to slow the growth of cancer cells and increase their susceptibility to therapy. Although this is yet theoretical, there are early indications that vitamin C may aid the immune system in identifying and combating tumors.
Partially correct
Was Pauling correct, then? The most reasonable explanation is that he overstated the promise and was partially correct for reasons he did not fully comprehend.
His promotion of vitamin C tablets as a potent cancer treatment was incorrect. High-dose vitamin C consumption has not been shown in extensive, meticulous trials to prolong the life of those with existing cancer.
Additionally, he was incorrect to claim that vitamin C could treat a wide range of ailments.
However, his suspicion that vitamin C might play a unique function in cancer treatment was not wholly unfounded. Long before we could demonstrate it, he had a feeling that really high doses administered intravenously would react quite differently from regular supplements.
Intravenous vitamin C has been shown to have distinct biological effects and to reach substantially higher blood levels.
Large, conclusive randomized trials demonstrating that high-dose intravenous vitamin C clearly extends life for the majority of cancer patients are still lacking. Until then, it ought to be viewed as experimental—promising enough to be investigated but not sufficiently established to take the place of conventional treatments. Clinics that provide pricey "immune boosts" should not be used for any purpose; instead, they should be used in clinical studies or in well monitored medical settings.
The narrative surrounding vitamins and cancer is still developing. If there is one lesson to be learned from the vitamin C and cancer story, it is that science rarely proceeds in a straight line.
A daring notion, some erroneous early research, a violent backlash – and then, years later, a quieter, more deliberate revisit to the question.
Pauling was not only deluded, even though he may never be completely justified. He might have seen a glimmer of truth in his zeal long before the rest of us learned how to find it.
0 Comments